Why Merit Medical Systems (MMSI) Is Getting Fresh Attention
Why this leadership change matters for Merit Medical Systems stock
Merit Medical Systems (MMSI) drew fresh investor attention after announcing that Sheri Lewis will become Executive Vice President of Global Operations, with long-serving operations leader Mr. Peterson shifting into a Senior Advisor role.
Merit Medical Systems shares trade at US$90.68, with a 30 day share price return of 6.67% and a 90 day share price return of 49.51%. Total shareholder return over three years is 41.91% and 26.74% over five years, suggesting momentum has been building around the business as investors weigh leadership continuity, operational execution and valuation together.
Scan how Merit Medical Systems compares to other operationally disciplined healthcare stocks by reviewing our hand picked list of solid balance sheet and fundamentals (53 results).
After a sharp 90 day move and a fresh operations hire, the issue now is whether most of the easy share price gains in Merit Medical Systems are already behind you or if the current valuation still points to further upside.
Most Popular Narrative: 9.6% Undervalued
The most followed narrative currently puts Merit Medical Systems fair value at $100.27, which sits above the last close of $90.68 and frames a modest valuation gap.
Ongoing investments in operational efficiency, manufacturing automation, and product portfolio expansion through innovation and strategic M&A are driving improved gross and operating margins (evidenced by record 21% non-GAAP operating margin), supporting higher cash flow and net earnings. Regulatory support for medical device innovation, including NTAP approval and ongoing CMS engagement for WRAPSODY CIE, alongside successful cross-selling of new product lines into existing channels, establish strong long-term catalysts for above-peer revenue growth and margin expansion once reimbursement uncertainties resolve.
Want to see what sits behind that margin story for Merit Medical Systems? The narrative leans on steadier revenue gains, rising profitability and a future earnings multiple that assumes investors keep paying up for that progress.
Result: Fair Value of $100.27 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Merit Medical Systems still faces clear risks, including potential further delays in WRAPSODY CIE reimbursement and higher costs if tariffs or global trade issues intensify.
Find out about the key risks to this Merit Medical Systems narrative.
Another View on Merit Medical Systems valuation
The fair value narrative frames Merit Medical Systems as 9.6% undervalued at $90.68 versus $100.27. Yet the current P/E of 37.2x is well above both the US Medical Equipment industry average of 27.5x and an estimated fair ratio of 25x, which suggests higher valuation risk. Which signal do you trust more right now?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With mixed signals on valuation and business momentum in Merit Medical Systems, it may be useful to act promptly, review the key data points yourself, and stress test your own thesis using our breakdown of 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond Merit Medical Systems?
If you stop with Merit Medical Systems, you could miss other opportunities that fit your style. Let Simply Wall Street’s screener help you uncover strong alternatives.
- Target resilient balance sheets by scanning the list of solid balance sheet and fundamentals (53 results) that pair financial strength with grounded fundamentals.
- Hunt for potential value opportunities by reviewing the 50 high quality undervalued stocks that combine quality metrics with compressed valuations.
- Prioritise stability and income by checking the 12 dividend fortresses that focus on higher yielding companies with staying power.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com